Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Covicompare-Janssen: Immunogenicity and safety of COVID-19 Vaccine Janssen in adults by age group
2021-003191-14Phase 3Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by CHU Saint-Etienne. Primary endpoints: Anti SARS-CoV-2 Spike IgG (ELISA test) at Day 28 and Maintenance or decay of anti SARS-CoV-2 Spike IgG up to Month 24. Started Jun 2021; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003191-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003191-14.